Trial watch: dexmedetomidine in cancer therapy
ABSTRACTDexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery...
Main Authors: | Killian Carnet Le Provost, Oliver Kepp, Guido Kroemer, Lucillia Bezu |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2024-12-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2327143 |
Similar Items
-
Trial watch: local anesthetics in cancer therapy
by: Killian Carnet Le Provost, et al.
Published: (2024-12-01) -
Trial watch: beta-blockers in cancer therapy
by: Killian Carnet Le Provost, et al.
Published: (2023-12-01) -
Editorial: Anesthesia and cancer: Friend or foe?
by: Lucillia Bezu, et al.
Published: (2022-12-01) -
Comparison of intraoperative hemodynamic and recovery pattern between opioid free and opioid based anaesthesia for minor day care gynaecological procedures
by: Pranjali Kurhekar, et al.
Published: (2023-04-01) -
Opioid-Free Anesthesia for Pain Relief After Laparoscopic Cholecystectomy: A Prospective Randomized Controlled Trial
by: Yu JM, et al.
Published: (2023-10-01)